ation has the same clinical benefits in treating ARDS that have been seen in animal models, and whether ACE2-Fc administration could alleviate ARDS in 2019-nCoV patients.
The proposed therapy for 2019-nCoV patients would consist of the extracellular domain of the ACE2 protein fused to a